Search result for 'vevzuo'

Biocon Biologics settles with Amgen to commercialize Denosumab biosimilars (Vevzuo & Evfraxy) in Europe starting Dec 2, 2025.

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & postmenopausal women.

Biocon Biologics receives European Commission approval for Vevzuo and Evfraxy, biosimilars of Denosumab, used to treat various bone diseases. This marks significant progress in expanding access to...